Related Experiment Videos
The effect of sotalol on plasma lipoproteins and apolipoproteins
Insights
Sotalol treatment in hypertensive patients increased plasma triglyceride levels but did not significantly alter other lipoproteins. This suggests Sotalol
Area of Science:
- Cardiology
- Clinical Pharmacology
- Biochemistry
Background:
- Hypertension is a major risk factor for cardiovascular disease.
- Beta-blockers are commonly used to manage hypertension.
- The impact of Sotalol on plasma lipoproteins requires further investigation.
Purpose of the Study:
- To assess the effects of Sotalol on plasma lipoprotein profiles in hypertensive patients.
- To compare Sotalol's lipid profile changes with other beta-blockers.
Main Methods:
- Ten hypertensive subjects received Sotalol 320 mg/day.
- Plasma lipoproteins were measured at baseline, 6 weeks, and 6 months.
- Heart rate, blood pressure, triglyceride, cholesterol, and apolipoprotein levels were analyzed.
Main Results:
- Heart rate significantly decreased (p<0.01).
- Mean blood pressure showed a non-significant trend downwards.
- Plasma triglyceride levels significantly increased at 6 months (p<0.005).
- No significant changes were observed in VLDL, LDL, HDL cholesterol, or apolipoproteins (Apo A-I, Apo A-II, Apo B).
Conclusions:
- Sotalol influences plasma lipoproteins similarly to other non-cardioselective beta-blockers without intrinsic sympathomimetic activity.
- Sotalol use does not appear to increase atherosclerosis risk compared to other beta-blockers.
Abstract:
Plasma lipoproteins were estimated in ten hypertensive subjects (mean age 51 +/- 11.2 yr), before, 6 wk and 6 mth following treatment with Sotalol 320 mg/day. Heart rate fell sequentially throughout the study (p less than 0.01) and although there was a sequential fall in mean blood pressure this did not reach statistical significance. There was a significant increase in plasma triglyceride concentration from a basal value of 1.87 +/- 1.064 to 2.50 +/- 0.877 mmol/l (p less than 0.005) at 6 mth. No significant change was found in very low density, low density and high density lipoprotein cholesterol or apolipoprotein concentrations (Apo A-I, Apo A-II, Apo B). We conclude that Sotalol exerts a similar influence on plasma lipoproteins as other non-cardioselective beta-adrenoceptor blockers without intrinsic sympathomimetic activity and its use does not constitute an increased risk of developing atherosclerosis, when compared with other beta-blockers.